BioCentury | Dec 3, 2012
Company News

Arena, Ildong deal

...Arena granted Ildong exclusive rights to develop and commercialize temanogrel in South Korea to treat thrombotic...
...stroke and peripheral artery disease. Ildong is responsible for conducting a Phase I trial with temanogrel...
...to use data generated by Ildong to develop and commercialize temanogrel outside of South Korea. Temanogrel...
BioCentury | Jul 14, 2008
Clinical News

APD791: Phase Ib data

...inhibition of serotonin-mediated amplification of platelet aggregation. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Product: APD791...
BioCentury | Jan 14, 2008
Clinical News

APD791: Phase Ia data

...Phase Ia trial in 90 volunteers, APD791 was well tolerated without any dose-related adverse events. APD791...
...and at higher doses, the compound's half-life was 11 hours. Patients received oral doses of APD791...
...maximum tolerated dose has not been determined. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Product: APD791...
BioCentury | Jul 23, 2007
Clinical News

APD791: Phase I started

...oral APD791 in 72 healthy adult volunteers. Arena Pharmaceuticals Inc. (ARNA), San Diego, Calif. Product: APD791...
Items per page:
1 - 4 of 4